Avandia

FDA panel gives diabetes drug Avandia a limited victory

A Food and Drug Administration advisory panel has voted to ease measures that limit patient access to the diabetes pill Avandia.

Avandia gets FDA win, but is unlikely to dominate market again

By

A Food and Drug Administration advisory panel has voted to ease measures that limit patient access to the diabetes pill Avandia. Many panelists, however, said precautions are still needed.

GSK will pay $90 million to settle diabetes drug allegations

GlaxoSmithKline will pay a $90 million settlement to 38 states that claimed it unlawfully promoted its diabetes treatment Avandia (rosiglitazone). As a result of the settlement, GSK must change the way it promotes its diabetes drugs, including Avandia.

GSK agrees to pay $90 million to settle diabetes drug allegations

By

GlaxoSmithKline will pay a $90 million settlement to 38 states that claimed it unlawfully promoted its diabetes treatment Avandia (rosiglitazone). The attorneys general of several states confirmed the action on Thursday.

GlaxoSmithKline will pay $3 billion to settle criminal charges

In what is the biggest healthcare fraud settlement in U.S. history, drug maker GlaxoSmithKline will pay $3 billion and plead guilty to illegally promoting prescription drugs

Drug company to pay $3 billion to settle criminal charges

Drug company to pay $3 billion to settle criminal charges

In what is the biggest healthcare fraud settlement in U.S. history, drugmaker GlaxoSmithKline will pay $3 billion and plead guilty to illegally promoting prescription drugs.

FDA puts heavy restrictions on Avandia

The Food and Drug Administration announced Wednesday that it will pull Avandia from retail pharmacy shelves due to the diabetes drug's cardiovascular threat to patients.

Popular diabetes medication linked to heart attack, death

A new study links the popular diabetes drug Avandia with an increased risk of heart attack and death, which could have a considerable effect on public health, according to researchers.

Don't miss any McKnight's news

Featured Articles